STOCK TITAN
  1. Home
  2. SEC Filings
  3. ALMR
  4. [Form 4] Alamar Biosciences, Inc. Insider Trading Activity

Alamar Biosciences: Qiming entities sell 217,512 shares

The reported sales were held through four Qiming entities, with different weighted-average prices across the two transaction dates.

Filing Impact
(Neutral)
Filing Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Form Type
4

Rhea-AI Filing Summary

Alamar Biosciences, Inc. reported that four Qiming entities indirectly sold 217,512 shares of common stock on October 19 and 20, 2026. The shares were held of record by Qiming Managing Directors Fund VI, L.P., Qiming Venture Partners VI, L.P., Qiming Venture Partners VIII Investments, LLC, and Qiming Venture Partners VIII-HC, L.P. Reported weighted-average prices were $26.34 per share on October 19 and $26.63, $27.93 and $28.44 per share on October 20. No Rule 10b5-1 plan is reported.

Insider Qiming Corporate GP VI, Ltd., Qiming Managing Directors Fund VI, L.P., Qiming Venture Partners VI, L.P., Qiming GP VIII, LLC, Qiming Venture Partners VIII Investments, LLC, Qiming GP VIII-HC, LLC, Qiming Venture Partners VIII-HC, L.P.
Role 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
Sold 217,512 shs ($5.95M)
Type Security Shares Price Value
Sale Common Stock F6, F2 200 $26.63 $5K
Sale Common Stock F7, F2 1,947 $27.93 $54K
Sale Common Stock F8, F2 335 $28.44 $10K
Sale Common Stock F6, F3 7,415 $26.63 $197K
Sale Common Stock F7, F3 72,373 $27.93 $2.02M
Sale Common Stock F8, F3 12,447 $28.44 $354K
Sale Common Stock F6, F4 1,730 $26.63 $46K
Sale Common Stock F7, F4 16,887 $27.93 $472K
Sale Common Stock F8, F4 2,904 $28.44 $83K
Sale Common Stock F6, F5 2,072 $26.63 $55K
Sale Common Stock F7, F5 20,217 $27.93 $565K
Sale Common Stock F8, F5 3,477 $28.44 $99K
Sale Common Stock F1, F2 1,320 $26.34 $35K
Sale Common Stock F1, F3 49,044 $26.34 $1.29M
Sale Common Stock F1, F4 11,443 $26.34 $301K
Sale Common Stock F1, F5 13,701 $26.34 $361K
Holdings After Transaction: Common Stock — 1,851,350 shares (Indirect, See footnote)
Footnotes (8)
  1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.2 to $26.52, inclusive. The reporting person undertakes to provide to Alamar Biosciences, Inc., any security holder of Alamar Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes (1) through (4) to this Form 4.
  2. F2. These shares are held of record by Qiming Managing Directors Fund VI, L.P. ("Qiming Managing Directors"). Qiming Corporate GP VI, Ltd. ("Qiming Corporate") serves as the general partner of Qiming Managing Directors and may be deemed to have voting and dispositive power over the shares held by Qiming Managing Directors. Qiming Corporate disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
  3. F3. These shares are held of record by Qiming Venture Partners VI, L.P., ("Qiming Venture Partners VI"). Qiming Corporate, through one intermediary, serves as the indirect general partner of Qiming Venture Partners VI and may be deemed to have voting and dispositive power over the shares held by Qiming Venture Partners VI. Qiming Corporate disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
  4. F4. These shares are held of record by Qiming Venture Partners VIII Investments, LLC ("QVP VIII LLC"). Qiming GP VIII, LLC, through two parallel intermediaries, serves as the indirect general partner of QVP VIII LLC and may be deemed to have voting and dispositive power over the shares held by QVP VIII LLC. Qiming GP VIII, LLC disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
  5. F5. These shares are held of record by Qiming Venture Partners VIII-HC, L.P. ("QVP VIII-HC"). Qiming GP VIII-HC, LLC serves as the general partner of QVP VIII-HC and may be deemed to have voting and dispositive power over the shares held by QVP VIII-HC. Qiming GP VIII-HC, LLC disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
  6. F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.20 to $26.96, inclusive.
  7. F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.28 to $28.27, inclusive.
  8. F8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.28 to $28.73, inclusive.
Common shares sold 217,512 shares Reported sales on October 19 and 20, 2026
Weighted-average sale price $26.34 per share October 19, 2026
Weighted-average sale price $26.63 per share October 20, 2026
Weighted-average sale price $27.93 per share October 20, 2026
Weighted-average sale price $28.44 per share October 20, 2026
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
held of record regulatory
"These shares are held of record by Qiming Managing Directors Fund VI, L.P."
voting and dispositive power regulatory
"may be deemed to have voting and dispositive power"
beneficial ownership regulatory
"disclaims beneficial ownership of such shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ALMR shares did the Qiming entities sell, and at what prices?
The entities reported sales totaling 217,512 shares of ALMR common stock on October 19 and 20, 2026. Weighted-average prices were $26.34 per share on October 19 and $26.63, $27.93 and $28.44 per share on October 20. No Rule 10b5-1 plan is reported.

What price ranges were reported for the ALMR share sales?
On October 19, shares were sold in multiple transactions at prices ranging from $26.2 to $26.52, inclusive. On October 20, the reported weighted-average prices and corresponding ranges were $26.63 per share at $26.20 to $26.96, $27.93 per share at $27.28 to $28.27, and $28.44 per share at $28.28 to $28.73.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Available on EDGAR Accepted by SEC EDGAR
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Qiming Corporate GP VI, Ltd.
(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309
(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104
(City)(State)(Zip)
CAYMAN ISLANDS
(Country)		2. Issuer Name and Ticker or Trading Symbol
Alamar Biosciences, Inc. [ ALMR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
10/19/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock10/19/2026S1,320D$26.34(1)180,808ISee footnote(2)
Common Stock10/19/2026S49,044D$26.34(1)6,719,561ISee footnote(3)
Common Stock10/19/2026S11,443D$26.34(1)1,567,881ISee footnote(4)
Common Stock10/19/2026S13,701D$26.34(1)1,877,116ISee footnote(5)
Common Stock10/20/2026S200D$26.63(6)180,608ISee footnote(2)
Common Stock10/20/2026S1,947D$27.93(7)178,661ISee footnote(2)
Common Stock10/20/2026S335D$28.44(8)178,326ISee footnote(2)
Common Stock10/20/2026S7,415D$26.63(6)6,712,146ISee footnote(3)
Common Stock10/20/2026S72,373D$27.93(7)6,639,773ISee footnote(3)
Common Stock10/20/2026S12,447D$28.44(8)6,627,326ISee footnote(3)
Common Stock10/20/2026S1,730D$26.63(6)1,566,151ISee footnote(4)
Common Stock10/20/2026S16,887D$27.93(7)1,549,264ISee footnote(4)
Common Stock10/20/2026S2,904D$28.44(8)1,546,360ISee footnote(4)
Common Stock10/20/2026S2,072D$26.63(6)1,875,044ISee footnote(5)
Common Stock10/20/2026S20,217D$27.93(7)1,854,827ISee footnote(5)
Common Stock10/20/2026S3,477D$28.44(8)1,851,350ISee footnote(5)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
1. Name and Address of Reporting Person*
Qiming Corporate GP VI, Ltd.
(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309
(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104
(City)(State)(Zip)
CAYMAN ISLANDS
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Qiming Managing Directors Fund VI, L.P.
(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309
(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104
(City)(State)(Zip)
CAYMAN ISLANDS
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Qiming Venture Partners VI, L.P.
(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309
(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104
(City)(State)(Zip)
CAYMAN ISLANDS
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Qiming GP VIII, LLC
(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309
(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104
(City)(State)(Zip)
CAYMAN ISLANDS
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Qiming Venture Partners VIII Investments, LLC
(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309
(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104
(City)(State)(Zip)
CAYMAN ISLANDS
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Qiming GP VIII-HC, LLC
(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309
(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104
(City)(State)(Zip)
CAYMAN ISLANDS
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Qiming Venture Partners VIII-HC, L.P.
(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309
(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104
(City)(State)(Zip)
CAYMAN ISLANDS
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.2 to $26.52, inclusive. The reporting person undertakes to provide to Alamar Biosciences, Inc., any security holder of Alamar Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes (1) through (4) to this Form 4.
2. These shares are held of record by Qiming Managing Directors Fund VI, L.P. ("Qiming Managing Directors"). Qiming Corporate GP VI, Ltd. ("Qiming Corporate") serves as the general partner of Qiming Managing Directors and may be deemed to have voting and dispositive power over the shares held by Qiming Managing Directors. Qiming Corporate disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
3. These shares are held of record by Qiming Venture Partners VI, L.P., ("Qiming Venture Partners VI"). Qiming Corporate, through one intermediary, serves as the indirect general partner of Qiming Venture Partners VI and may be deemed to have voting and dispositive power over the shares held by Qiming Venture Partners VI. Qiming Corporate disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
4. These shares are held of record by Qiming Venture Partners VIII Investments, LLC ("QVP VIII LLC"). Qiming GP VIII, LLC, through two parallel intermediaries, serves as the indirect general partner of QVP VIII LLC and may be deemed to have voting and dispositive power over the shares held by QVP VIII LLC. Qiming GP VIII, LLC disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
5. These shares are held of record by Qiming Venture Partners VIII-HC, L.P. ("QVP VIII-HC"). Qiming GP VIII-HC, LLC serves as the general partner of QVP VIII-HC and may be deemed to have voting and dispositive power over the shares held by QVP VIII-HC. Qiming GP VIII-HC, LLC disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.20 to $26.96, inclusive.
7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.28 to $28.27, inclusive.
8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.28 to $28.73, inclusive.
Qiming Corporate GP VI, Ltd By: /s/ Ho Man LAM/Authorized Signatory10/21/2026
Qiming Managing Directors Fund VI, L.P. By: /s/ Ho Man LAM/Authorized Signatory10/21/2026
Qiming Venture Partners VI, L.P. By: /s/ Ho Man LAM/Authorized Signatory10/21/2026
Qiming GP VIII, LLC By: /s/ Ho Man LAM/Authorized Signatory10/21/2026
Qiming Venture Partners VIII Investments, LLC By: /s/ Ho Man LAM/Manager10/21/2026
Qiming GP VIII-HC, LLC By: /s/ Ho Man LAM/Authorized Signatory10/21/2026
Qiming Venture Partners VIII-HC, L.P. By: /s/ Ho Man LAM/Authorized Signatory10/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Keep reading

More on ALMR

All ALMR news

Trending in the feed

QGEN
QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer Open the live feed